DVAX vs JCI · rev $277.2M vs P/E 44, rev $23.60B
Dynavax Technologies Corporation (DVAX) versus Johnson Controls International PLC (JCI) — a side-by-side from cached financials, not a winner call.
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Latest reported DVAX revenue for 2024-12-31 was $277.2M. Net income was $27.3M. Revenue was up 19.4% from 2023-12-31 to 2024-12-31. DVAX currently screens at market cap $1.82B.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
DVAX currently screens at market cap $1.82B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Not investment advice. Open the DVAX and JCI stock pages for the full models.
Not investment advice.